Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Rev Fac Cien Med Univ Nac Cordoba ; 79(3): 228-234, 2022 09 16.
Artigo em Espanhol | MEDLINE | ID: mdl-36149077

RESUMO

Introduction: Hereditary predisposition syndromes to cancer represent 5-10% of cancer cases, the most studied being HBOC produced by mutations in the BRCA1/2 genes. Objectives: To describe clinical, histopathological and PV characteristics in patients with HBOC in Córdoba, Argentina and compare it with those without BRCA1/2 mutations. Methods: Cross-sectional, correlational and observational analysis of patients from Córdoba. The ANOVA, Student's t test contingency tables and Fisher exact test were used the significance level was α = 0.05. Results: 155 women with BC, OC and BC/OC were studied. 40 BRCA1 / 2 mutations were identified. No differences were found in the age of diagnosis between patients with and without BRCA1/2 mutations. A significant association was found between VP in BRCA1/2 and the type of cancer (p = 0.003); all cases with BC/OC presented mutations in BRCA1/2. No significant association was found between mutated/non-mutated and personal history, family background, and ER-PR-HER2. 23.1% and 38.1% of BC cases were TN in individuals with VP in BRCA 1 and 2, respectively. The prevalence of mutations was 25.8% and the prevalence of novel PV was 10.0%. Conclusions: Patients with BC-VP BRCA1/2 are associated with ductal histology, and younger age of presentation with VP BRCA1. We did not find significant differences in the age at diagnosis of BC between patients with BRCA1 and BRCA2 mutations, a higher proportion of BC TN is observed than in the general population. In our sample, the prevalence of BRCA1/2 mutations among patients who meet criteria for HBOC is 25.8%, with 10% new pathogenic variant.


Introducción: Los síndromes de predisposición hereditaria al cáncer representan un 5-10% de los casos de cáncer, el más estudiado es HBOC producido por mutaciones en los genes BRCA1/2. Objetivos: Describir características clínicas, histopatológicas y VP en pacientes con HBOC en Córdoba, Argentina y compararla con aquellas sin mutaciones en BRCA1/2. Métodos: Análisis transversal, correlacional y observacional de pacientes de Córdoba. Se utilizó la prueba ANOVA, t de Student, tablas de contingencia y prueba exacta de Fisher, el nivel de significancia fue α=0,05. Resultados: Se estudiaron 155 mujeres con CM, CO y CM/CO. Se identificaron 40 mutaciones en BRCA1/2. No se encontraron diferencias en edad de diagnóstico entre pacientes con y sin mutaciones en BRCA1/2. Se encontró asociación significativa entre VP en BRCA1/2 y el tipo de cáncer (p=0,003); todos los casos con CM/CO presentaron mutaciones en BRCA1/2. No se encontró asociación significativa entre mutados/no mutados y AP, AF, RE-RP-HER2. El 23.1% y 38.1% de los casos de CM fueron TN en individuos con VP en BRCA 1 y 2 respectivamente. La prevalencia de mutaciones fue 25,8% y la prevalencia de VP noveles del 10,0%. Conclusiones: Las pacientes con CM-VP BRCA1/2 están asociadas con histología ductal, y menor edad de presentación con VP BRCA1. No encontramos diferencias significativas en edad de diagnóstico del CM entre pacientes con mutaciones BRCA1 y BRCA2, se observa una mayor proporción CM TN que en la población en general. En nuestra muestra, la prevalencia de mutaciones en BRCA1/2 entre los pacientes que reúnen criterios para HBOC es del 25,8%, con 10% de VP noveles.


Assuntos
Neoplasias da Mama , Neoplasias Ovarianas , Argentina/epidemiologia , Proteína BRCA1/genética , Proteína BRCA2/genética , Neoplasias da Mama/genética , Estudos Transversais , Feminino , Genes BRCA2 , Humanos , Mutação , Neoplasias Ovarianas/diagnóstico , Neoplasias Ovarianas/genética , Neoplasias Ovarianas/patologia
3.
Hematology ; 14(6): 323-30, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19941738

RESUMO

OBJECTIVE: To determine the prevalence of JAK2 V617F mutation and its clinical correlation in patients with chronic myeloproliferative disorders (CMD): polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF). MATERIALS AND METHODS: Detection of JAK2 V617F mutation by allele specific-PCR. RESULTS: One hundred and three patients with CMD were included in the study. JAK2 V617F distribution was PV 40/45 (89%), ET 30/43 (69%), and IMF 7/15 (47%). In PV and ET patients only, 18 had thrombosis at diagnosis and 12 during follow-up (these were microvascular: 11, venous: 7 and arterial: 12); of these 28/70 (40%) were JAK2pos versus 2/18 (11%) JAK2neg; P=0.02. In a median of 4 years, two patients with PV JAK2pos evolved to myelofibrosis and one patient with PV presented in leukemic transformation (JAK2pos before and after transformation); six patients died: four patients with IMF and two patients with PV. CONCLUSIONS: We found an association between JAK2 V617F and thrombotic events in patients with PV and ET.


Assuntos
Alelos , Janus Quinase 2/genética , Mutação de Sentido Incorreto , Transtornos Mieloproliferativos/genética , Adulto , Idoso , Idoso de 80 Anos ou mais , Substituição de Aminoácidos , Doença Crônica , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Transtornos Mieloproliferativos/complicações , Reação em Cadeia da Polimerase , Estudos Prospectivos , Trombose/etiologia , Trombose/genética
4.
Medicina (B Aires) ; 64(6): 504-8, 2004.
Artigo em Espanhol | MEDLINE | ID: mdl-15637827

RESUMO

Over the past years, considerable effort has been directed toward the identification of risk factors associated with the increasing incidence of cutaneous melanoma in white populations worldwide. Limited data are available from Argentine populations concerning risk factors for malignant melanoma. A case-control study was performed in Cordoba to estimate the risk factors for cutaneous malignant melanoma. The study group comprised 65 patients and 195 controls, matched by age and sex. The following risk factors were significant in the univariate analysis: European grandparents, blonde and brown hair, fair skin tone, light colored and brown eyes, presence of freckles and melanocytic nevi, severe sunburns before the age of 18 years, recreational sun exposure, family history of malignant melanoma. In the multivariate analysis, European grandparents (OR 2.27, IC95% 1.08 to 3.46), fair skin (OR 4.99, IC95% 2.72 to 7.28), severe sunburns before the age of 18 (OR 6.47, IC95% 5.29 to 7.65), and family history of malignant melanoma (OR 1525, IC95% 1467 to 1584), remain as independent risk factors for malignant melanoma. The results of the current study are similar to those obtained in other populations.


Assuntos
Melanoma/etiologia , Neoplasias Cutâneas/etiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Argentina/epidemiologia , Métodos Epidemiológicos , Feminino , Humanos , Masculino , Melanoma/epidemiologia , Pessoa de Meia-Idade , Neoplasias Cutâneas/epidemiologia
5.
Medicina [B Aires] ; 64(6): 504-8, 2004.
Artigo em Espanhol | BINACIS | ID: bin-38503

RESUMO

Over the past years, considerable effort has been directed toward the identification of risk factors associated with the increasing incidence of cutaneous melanoma in white populations worldwide. Limited data are available from Argentine populations concerning risk factors for malignant melanoma. A case-control study was performed in Cordoba to estimate the risk factors for cutaneous malignant melanoma. The study group comprised 65 patients and 195 controls, matched by age and sex. The following risk factors were significant in the univariate analysis: European grandparents, blonde and brown hair, fair skin tone, light colored and brown eyes, presence of freckles and melanocytic nevi, severe sunburns before the age of 18 years, recreational sun exposure, family history of malignant melanoma. In the multivariate analysis, European grandparents (OR 2.27, IC95


1.08 to 3.46), fair skin (OR 4.99, IC95


2.72 to 7.28), severe sunburns before the age of 18 (OR 6.47, IC95


5.29 to 7.65), and family history of malignant melanoma (OR 1525, IC95


1467 to 1584), remain as independent risk factors for malignant melanoma. The results of the current study are similar to those obtained in other populations.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...